Melior Discovery Selected as Preclinical CRO to Support Linnaeus Therapeutics' ARPA-H PROSPR Program

PartnershipLNS8801Positive

AI Analysis

Summary

Melior Discovery has been selected as a preclinical CRO to conduct in vivo pharmacology studies supporting Linnaeus Therapeutics' ARPA-H PROSPR-funded development of LNS8801 for healthspan preservation.

Outcome Details

Melior Discovery selected as preclinical CRO to conduct in vivo pharmacology studies

Importance:4/10

Sentiment:

0.50

CRO partnershippreclinicalARPA-H fundinghealthspan

Read the original article

Published by PR Newswire Pharma on July 21, 2026 1:00 PM

Read Original